Source-grounded facts extracted from BRUKER CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BRUKER CORP shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-05-21 meeting.
“The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2026 was approved based on the following votes: For Against Abstain 138,544,738 618,216 29,744”
BRUKER CORP shareholders approved Advisory Vote on the 2025 Compensation of Named Executive Officers at the 2026-05-21 meeting.
“The proposal to approve, on an advisory basis, the 2025 compensation of the named executive officers as disclosed in the Company’s proxy statement for the 2026 Annual Meeting was approved based on the following votes: For Against Abstain Broker Non-Votes 127,190,553 5,748,270 60,390 6,193,485”
BRUKER CORP shareholders approved Election of Directors at the 2026-05-21 meeting.
“The following director nominees were elected to serve as Class II members of the Company’s board of directors, each to serve for a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified based on the following votes : Nominees for Class II director: For Withheld Broker Non-Votes Laura A. Francis 136,149,316 4,841,094 6,193,485 John J. (Jack) Phillips 139,036,356 1,954,054 6,193,485 Hermann F. Requardt, Ph.D. 129,777,851 11,212,559 6,193,485”
BRUKER CORP shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2026 at the 2026-05-21 meeting.
“The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2026 was approved based on the following votes”
BRUKER CORP shareholders approved Advisory vote on the 2025 compensation of named executive officers at the 2026-05-21 meeting.
“The proposal to approve, on an advisory basis, the 2025 compensation of the named executive officers as disclosed in the Company’s proxy statement for the 2026 Annual Meeting was approved based on the following votes”
BRUKER CORP shareholders approved Election of Class II directors at the 2026-05-21 meeting.
“The following director nominees were elected to serve as Class II members of the Company’s board of directors, each to serve for a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified based on the following votes”
BRUKER CORP reported FY2026 results: revenue $3.57 to $3.60 billion, EPS $2.10 to $2.15. Guidance reaffirmed.
“Reconfirming previous FY2026 guidance: o Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% o Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind”
BRUKER CORP reported the three months ended March 31, 2026 results: revenue $823.4 million, EPS $0.02.
“Bruker Reports First Quarter 2026 Financial Results • Q1 2026 revenues of $823.4 million, up 2.7% year-over-year (yoy), down 4.4% organically • Q1-26 GAAP diluted earnings per share (EPS) $0.02; non-GAAP diluted EPS $0.31”
BRUKER CORP: Filed Certificate of Designations to establish terms of 6.375% Mandatory Convertible Preferred Stock, Series A (effective 2025-09-08).
“the Company filed a Certificate of Designations (the “Certificate of Designations”) with the Secretary of State of the State of Delaware on September 8, 2025 to establish the designations, powers, preferences and rights of the Mandatory Convertible Preferred Stock”
Laura Francis was appointed as director at BRUKER CORP.
“appointed Laura Francis to fill the newly created vacancy on the Board, effective as of February 18, 2025.”
Thomas Bures was appointed as Chief Accounting Officer at BRUKER CORP.
“On January 13, 2025, Thomas Bures was appointed to serve as the Chief Accounting Officer of Bruker Corporation (the “Company”), effective immediately.”
Philip Ma resigned as Director at BRUKER CORP.
“On August 5, 2024, Dr. Philip Ma informed the board of directors (the “Board”) of Bruker Corporation (the “Company”) of his resignation from the Board, effective immediately, to concentrate his efforts on his own company.”
BRUKER CORP reported the first quarter ended March 31, 2024 results: revenue $721.7 million, EPS $0.35. Guidance raised.
“Bruker Reports First Quarter 2024 Financial Results • Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenue up 5.5% yoy • Q1 2024 GAAP EPS of $0.35; non-GAAP EPS of $0.53 • Updated FY 2024 guidance: • Revenue $3.29 to $3.35 billion, up $60 million from prior guidance, implying reported growth of 11% to 13% yoy. • Organic revenue growth maintained at 5% to 7% yoy • CER revenue growth of 12% to 14% yoy, including closed Chemspeed and ELITech acquisitions, up from prior guidance of 8% to 10% yoy • Non-GAAP EPS of $2.79 to $2.84, up $0.08 from prior guidance, including ELITech EPS accretion, but excluding still pending EPS-dilutive NanoString acquisition”
BRUKER CORP entered into Asset Purchase Agreement with NanoString Technologies, Inc. valued at $392.6 million (effective 2024-04-17).
“On April 17, 2024, Bruker Corporation (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with NanoString Technologies, Inc., a Delaware corporation (“Seller”), as the result of the Company being selected as the successful bidder in a sale authorized by the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) pursuant to, inter alia, sections 105, 363, and 365 of the United States Bankruptcy Code (the “Bankruptcy Code”).”
BRUKER CORP incurred term loan of CHF 150 million seven-year term loan facility with Bank of America, N.A. at SARON plus a margin ranging from 1.250% to 1.750% maturing seven-year.
“the Seven-Year Term Loan Agreement provides for a CHF 150 million seven-year term loan facility”
BRUKER CORP incurred term loan of CHF 150 million five-year term loan facility with Bank of America, N.A. at SARON plus a margin ranging from 1.000% to 1.500% maturing five-year.
“On March 29, 2024 (the “Effective Date”), the Company, as borrower, entered into (i) a term loan agreement with Bank of America, N.A., as administrative agent, BofA Securities, Inc., JPMorgan Chase Bank, N.A., TD Bank, N.A.”
BRUKER CORP incurred term loan of CHF 150 million three-year term loan facility with Bank of America, N.A. at SARON plus a margin ranging from 1.000% to 1.500% maturing three-year.
“The Three- and Five-Year Term Loan Agreement provides for a (i) CHF 150 million three-year term loan facility”
BRUKER CORP entered into Three- and Five-Year Term Loan Agreement with Bank of America, N.A. valued at CHF 150 million three-year term loan facility and CHF 150 million five-year term loan facility (effective 2024-04-02).
“The Three- and Five-Year Term Loan Agreement provides for a (i) CHF 150 million three-year term loan facility and (ii) CHF 150 million five-year term loan facility”
BRUKER CORP reported three months and year ended December 31, 2023 results: revenue Q4 2023 revenues of $854.5 million, EPS Q4 2023 GAAP EPS of $1.41.
“On February 13, 2024, Bruker Corporation issued a press release announcing financial results as of and for the three months and year ended December 31, 2023.”
BRUKER CORP incurred senior notes of CHF 50 million aggregate principal amount of 2.60% Series A Senior Notes due April 15, 2036 and CHF 50 million aggregate with institutional accredited investors named therein at 2.60% and 2.62% maturing April 15, 2036 and April 15, 2039.
“On February 8, 2024, Bruker Corporation (the “Company”) entered into a note purchase agreement among the Company and the institutional accredited investors named therein (the “Note Purchase Agreement”), pursuant to which the Company will issue and sell (i) CHF 50 million aggregate principal amount of 2.60% Series A Senior Notes due April 15, 2036 (the “Series A Notes”) and (ii) CHF 50 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2039 (the “Series B Notes” together with the Series A Notes, the “Notes”)”
BRUKER CORP entered into Note Purchase Agreement with unknown valued at Not specified in excerpt (effective 2024-02-12).
“Terms used in this Item 1.01 and not otherwise defined herein have the meanings given to them in the Note Purchase Agreement. Interest on the Notes is payable semi-annually on April 15 and October 15 of each year, commencing April 15 or October 15, 2024. The Notes are unsecured obligations of the Company and are fully and unconditionally guaranteed by certain of the Company’s subsidiaries.”
BRUKER CORP incurred senior notes of CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 at 2.71% maturing April 15, 2039.
“On February 1, 2024, the Bruker Corporation (the “Company”) entered into a note purchase agreement among the Company and the institutional accredited investors named therein (the “Note Purchase Agreement”), pursuant to which the Company will issue and sell (i) CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 (the “Series A Notes”), (ii) CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 (the “Series B Notes”) and (iii) CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 (the “Series C Notes” together with the Series A Notes and the Series B Notes, the “Notes”) in an offering exempt from the registration requirements of the Securities Act of 1933, as amended.”
BRUKER CORP incurred senior notes of CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 at 2.62% maturing April 15, 2036.
“On February 1, 2024, the Bruker Corporation (the “Company”) entered into a note purchase agreement among the Company and the institutional accredited investors named therein (the “Note Purchase Agreement”), pursuant to which the Company will issue and sell (i) CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 (the “Series A Notes”), (ii) CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 (the “Series B Notes”) and (iii) CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 (the “Series C Notes” together with the Series A Notes and the Series B Notes, the “Notes”) in an offering exempt from the registration requirements of the Securities Act of 1933, as amended.”
BRUKER CORP incurred senior notes of CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 at 2.56% maturing April 15, 2034.
“On February 1, 2024, the Bruker Corporation (the “Company”) entered into a note purchase agreement among the Company and the institutional accredited investors named therein (the “Note Purchase Agreement”), pursuant to which the Company will issue and sell (i) CHF 50 million aggregate principal amount of 2.56% Series A Senior Notes due April 15, 2034 (the “Series A Notes”), (ii) CHF 146 million aggregate principal amount of its 2.62% Series B Senior Notes due April 15, 2036 (the “Series B Notes”) and (iii) CHF 135 million aggregate principal amount of its 2.71% Series C Senior Notes due April 15, 2039 (the “Series C Notes” together with the Series A Notes and the Series B Notes, the “Notes”) in an offering exempt from the registration requirements of the Securities Act of 1933, as amended.”
BRUKER CORP entered into Note Purchase Agreement.
“The foregoing summary description of the Note Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Note Purchase Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.”
BRUKER CORP amended credit facility of from $600 million to $900 million with several banks or other financial institutions or entities from time to time party thereto as lenders at SOFR plus a margin ranging from 1.000% to 1.500% maturing January 18, 2029.
“herein have the meanings given to them in the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement increases the aggregate principal amount from $600 million to $900 million and extends the maturity date to January 18, 2029, as may be further extended by the Company for the periods and on the terms set forth in the Amended and”
BRUKER CORP amended Amended and Restated Credit Agreement with Bank of America, N.A. valued at increases the aggregate principal amount from $600 million to $900 million (effective 2024-01-18).
“The Amended and Restated Credit Agreement increases the aggregate principal amount from $600 million to $900 million and extends the maturity date to January 18, 2029”
BRUKER CORP reported the full year 2023 results: revenue greater than $2.94 billion.
“The Company also provided current preliminary expectation that revenue for the full year 2023 is greater than $2.94 billion, including organic revenue growth greater than 13% year-over-year.”
BRUKER CORP reported the fourth quarter of 2023 results: revenue greater than $830 million.
“On January 8, 2024, during its scheduled presentation at the 42nd Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for the fourth quarter of 2023 is greater than $830 million including organic revenue growth greater than 12% year-over-year and that fourth quarter 2023 BSI bookings were solid.”
BRUKER CORP reported the first nine months ended September 30, 2023 results: revenue $2.11 billion, EPS $1.50 GAAP diluted EPS; $1.88 non-GAAP diluted EPS. Guidance raised.
“First Nine Months of 2023 Financial Results For the first nine months of 2023, Bruker’s revenues were $2.11 billion, an increase of 15.8% from $1.82 billion in the first nine months of 2022.”
BRUKER CORP reported the third quarter ended September 30, 2023 results: revenue $742.8 million, EPS $0.60 GAAP diluted EPS; $0.74 non-GAAP diluted EPS. Guidance raised.
“Bruker Reports Third Quarter 2023 Financial Results • Q3 2023 revenues of $742.8 million, up 16.3% year-over-year (yoy); organic revenue up 10.9% yoy • Q3 2023 GAAP EPS $0.60; non-GAAP EPS $0.74, up 12.1% yoy • Bruker increases FY 2023 revenue guidance to $2.88-$2.91 billion”
BRUKER CORP reported the three and six months ended June 30, 2023 results: revenue $681.9 million, EPS $0.39. Guidance raised.
“Section 9 – Financial Statements and Exhibits --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Bruker Reports Second Quarter 2023 Financial Results • Q2 2023 revenues of $681.9 million, up 15.9% year-over-year (yoy); organic revenue up 13.5% yoy • Q2 2023 GAAP EPS $0.39; non-GAAP EPS $0.50, up 11.1% yoy • Bruker increases FY 2023 revenue guidance to $2.85-$2.90”
BRUKER CORP shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-07 meeting.
“Proposal No. 4 - Ratification of the Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2023 was approved based on the following votes: For Against Abstain Broker Non-Votes 142,988,240 181,093 24,593 N/A”
BRUKER CORP shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Named Executive Officer Compensation at the 2023-06-07 meeting.
“Proposal No. 3 - Advisory Vote on the Frequency of Future Advisory Votes on Named Executive Officer Compensation The result of the advisory vote on the frequency of future advisory votes on the compensation of named executive officers is set forth below: Every Year Every Two Years Every Three Years Abstain Broker Non-Votes 100,956,791 4,842 40,135,378 26,896 N/A”
BRUKER CORP shareholders approved Advisory Vote on the 2022 Compensation of Named Executive Officers at the 2023-06-07 meeting.
“Proposal No. 2 - Advisory Vote on the 2022 Compensation of Named Executive Officers The proposal to approve, on an advisory basis, the 2022 compensation of the named executive officers as disclosed in the Company’s proxy statement for the 2023 Annual Meeting of Stockholders was approved based on the following votes: For Against Abstain Broker Non-Votes 135,795,935 5,297,389 30,583 2,070,019”
BRUKER CORP shareholders approved Election of Class II Directors at the 2023-06-07 meeting.
“Proposal No. 1 - Election of Directors Nominees for Class II director: For Withheld Broker Non-Votes Cynthia M. Friend, Ph.D. 137,126,233 3,997,674 2,070,019 Philip Ma, Ph.D. 134,888,471 6,235,436 2,070,019 Hermann Requardt, Ph.D 132,217,047 8,906,860 2,070,019”
BRUKER CORP reported FY 2023 results: revenue $2.83-$2.88 billion, EPS $2.55-$2.60. Guidance raised.
“Bruker increases FY 2023 guidance for revenue to $2.83-$2.88 billion and for non-GAAP EPS to $2.55-$2.60; implies revenue growth to 12%-14%, and organic revenue growth of 9%-11% yoy”
BRUKER CORP reported the three months ended March 31, 2023 results: revenue $685.3 million, EPS $0.52.
“• Q1 2023 revenues of $685.3 million, up 15.2% year-over-year (yoy); organic revenue up 17.6% yoy • Q1 2023 GAAP EPS $0.52; non-GAAP EPS $0.64, up 30.6% yoy”
BRUKER CORP reported FY 2023 results: revenue $2.81 to $2.86 billion, EPS $2.52 to $2.57. Guidance initiated.
“For FY 2023, Bruker expects revenue of $2.81 to $2.86 billion, or 11% to 13% year-over-year reported revenue growth”
BRUKER CORP reported the year ended December 31, 2022 results: revenue $2.531 billion, EPS $1.99.
“• Q4 2022 revenues $708.4 million, up 3.6% year-over-year (yoy); organic revenue growth of 8.9% • Q4 2022 GAAP EPS $0.66; non-GAAP EPS $0.74, up 25.4% yoy • FY 2022 revenues $2.531 billion, up 4.7% yoy; organic revenue growth of 10.2% • FY 2022 GAAP EPS $1.99; non-GAAP EPS $2.34, up 11.4% yoy • Bruker expects FY 2023 organic revenue growth of 8% to 10% yoy”
BRUKER CORP reported the three months ended December 31, 2022 results: revenue $708.4 million, EPS $0.66.
“9 – Financial Statements and Exhibits --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Bruker Reports Fourth Quarter and Fiscal Year 2022 Financial Results • Q4 2022 revenues $708.4 million, up 3.6% year-over-year (yoy); organic revenue growth of 8.9% • Q4 2022 GAAP EPS $0.66; non-GAAP EPS $0.74, up 25.4% yoy • FY 2022 revenues $2.531 billion, up 4.7% yoy; organic”
BRUKER CORP updated its 2023 guidance (initiated).
“The Company also provided initial guidance for 2023 for organic revenue growth up mid-to-high single digit percent year-over-year”
BRUKER CORP updated its fourth quarter of fiscal year 2022 guidance (initiated).
“Bruker Corporation (the "Company") stated that its current preliminary expectation for revenue for the fourth quarter of fiscal year 2022 to be up low single digits percent year-over-year”
BRUKER CORP reported fiscal year 2022 results: EPS $2.29 to $2.33. Guidance raised.
“Bruker continues to expect FY 2022 non-GAAP EPS of $2.29 to $2.33, unchanged from prior guidance”
BRUKER CORP reported first nine months of 2022 results: revenue $1.822 billion, EPS $1.33. Guidance raised.
“For the first nine months of 2022, Bruker’s revenues were $1.822 billion”
BRUKER CORP reported third quarter of 2022 results: revenue $638.9 million, EPS $0.59. Guidance raised.
“Bruker’s revenues for the third quarter of 2022 were $638.9 million”
Philip Ma was appointed as Director at BRUKER CORP.
“the Board approved an increase in the number of directors to expand the size of the Board by one director to a total of eleven directors, with such additional director assigned to Class II, and appointed Dr. Philip Ma to fill the newly created vacancy on the Board, effective as of April 1, 2022.”
Marc Kastner departed as Director at BRUKER CORP.
“Dr. Marc Kastner informed the Board of Directors (“Board”) of Bruker Corporation (the “Company”) of his decision to retire and not to stand for re-election as a Class II director when his current term expires at the Company’s 2023 Annual Meeting of Stockholders”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.